Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout...
December 10 2020 - 8:30AM
Daxor Corporation (NYSE MKT: DXR), an investment company with
innovative medical instrumentation and biotechnology operations
focused on blood volume measurement, today announces additional
acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major
medical centers across the U.S.
A leading academic medical center in Northeast
purchased the BVA-100® analyzer and has incorporated the BVA blood
test into their inpatient treatment protocol for heart failure
patients. A medical center in the Midwest purchased the BVA-100®
analyzer for use in their outpatient heart failure clinic. In
addition to these new purchases, three hospitals across the country
have renewed their paid support agreements solidifying their
commitment to the value of blood volume analysis in treating
patients with volume derangements.
“Sales continue to excel despite the pandemic,
further validating the clinical benefits of our technology in both
inpatient and outpatient use,” said Michael Feldschuh, President
and CEO of Daxor Corporation. “The BVA-100® blood test provides a
simple, inexpensive, objective measurement of volume status and
composition providing clinicians with actionable results to
optimize fluid management and improve patient outcomes while
driving substantial cost savings throughout the healthcare
system.”
“We are encouraged by the continued growth and
implementation of our market-leading, FDA-cleared diagnostic blood
volume test as a new measure of care. Cost-benefit analysis shows
BVA-guided care is 80 percent less costly than other therapies of
equal patient benefit in our healthcare system while also
demonstrating an impressive average life-extension of 2.32
quality-adjusted life years,” said Jean Oertel, Vice President of
Commercialization and Customer Experience. “Daxor’s growing market
share is driven by our expanded team of territory managers and
clinical experts who are supporting our customers to achieve
dramatic reductions in mortality rates and hospital
readmissions.”
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. The BVA technology enhances hospital performance metrics in
a broad range of surgical and medical conditions, including heart
failure and critical care, by informing treatment strategies,
resulting in significantly improved multiple measures of patient
outcomes. Daxor's mission is to advance healthcare by enabling
optimal fluid management with blood volume analysis. Daxor’s vision
is optimal blood volume for all. For more information, please visit
our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Jul 2023 to Jul 2024